Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 341 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: OAG - Open-Angle Glaucoma Clear all
Completed Phase 1 Interventional

Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension

NCT00515424
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Timeline
Started 2007
U.S. locations
5
States / cities
Artesia, California • Rochester, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

NCT01789736
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
21
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

NCT01052558
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Inject (GTS400), Cataract Surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT00845299
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost punctal plug, artificial tears preserved with Benzalkonium Chloride
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00372931
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
AL-37807
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

NCT05411198
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
XEN45 (Glaucoma Gel Stent)
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 1, 2026, 10:36 PM EDT
Active, not recruiting No phase listed Observational

Advanced Glaucoma Progression Study

NCT01742819
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Chronic Angle Closure Glaucoma
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

NCT02537015
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

NCT01731002
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT00051142
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Travoprost, Latanoprost
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 1, 2026, 10:36 PM EDT
Not listed Phase 2 Interventional

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 1, 2026, 10:36 PM EDT
Completed No phase listed Observational

Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

NCT02151318
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 1, 2026, 10:36 PM EDT
Terminated Not applicable Interventional Results available

A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma

NCT04465630
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fayetteville, Arkansas • Newport Beach, California • Petaluma, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 1, 2026, 10:36 PM EDT
Completed No phase listed Observational Results available

A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

NCT05044793
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Wichita, Kansas • Oklahoma City, Oklahoma • Jenkintown, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Evaluation of Pascal Laser Trabeculoplaty

NCT00838721
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
laser trabeculoplasty
Other
Lead sponsor
Santa Clara Valley Health & Hospital System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Safety and Feasibility of the ELIOS System in POAG Patients

NCT05999006
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
ELIOS Procedure
Device
Lead sponsor
Elios Vision, Inc.
Industry
Eligibility
45 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 1, 2026, 10:36 PM EDT
Completed No phase listed Observational

Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics

NCT01342406
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
40 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 4 Interventional

Assessing Cosopt Switch Patients

NCT00273442
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions
timolol maleate, dorzolamide/timolol maleate fixed combination
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 1, 2026, 10:36 PM EDT
Not listed Not applicable Interventional

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

NCT00440336
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Cosopt, Xalatan
Drug
Lead sponsor
Advanced Glaucoma Specialists
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Reading, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Phase 2Phase 3 Interventional

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

NCT07354516
View directory record Official record
Conditions
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions
QLS-111-FDC, Latanoprost (0.005%)
Combination Product · Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 1, 2026, 10:36 PM EDT
Completed Not applicable Interventional

A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction

NCT02784249
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
Procedure · Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 1, 2026, 10:36 PM EDT